Clinical trial · no report yet · Phase 3
OReO
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
- NCT03106987 ↗
- Completed
- AstraZeneca
- 27 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 16 | |
| Podcasts | 10 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Active Comparator: Olaparib tablets; Placebo
- Arms
- Active Comparator: Olaparib · Experimental
- Placebo Comparator: Placebo · Placebo comparator
- Enrollment
- 220
- Primary outcomes
- Efficacy: Progression-free Survival (PFS)
- Sponsor
- AstraZeneca with European Network of Gynaecological Oncological Trial Groups (ENGOT)
- Start
- Jun 8, 2017
- Primary completion
- Feb 15, 2021
- Results posted
- Yes
- Registry record
- NCT03106987 · updated Oct 7, 2022
Publications
linked from the registry- Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marme F, Lindemann K, Colombo N, Madry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Perez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023 Dec;34(12):1152-1164. doi: 10.1016/j.annonc.2023.09.3110. Epub 2023 Oct 4. PubMed 37797734